Browse PGR

Summary
SymbolPGR
Nameprogesterone receptor
Aliases NR3C3; nuclear receptor subfamily 3 group C member 3
Chromosomal Location11q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Cytoplasm. Note=Nucleoplasmic shuttling is both hormone- and cell cycle-dependent. On hormone stimulation, retained in the cytoplasm in the G(1) and G(2)/M phases.; SUBCELLULAR LOCATION: Isoform A: Nucleus. Cytoplasm. Note=Mainly nuclear.; SUBCELLULAR LOCATION: Isoform 4: Mitochondrion outer membrane
Domain PF00104 Ligand-binding domain of nuclear hormone receptor
PF02161 Progesterone receptor
PF00105 Zinc finger
Function

The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Depending on the isoform, progesterone receptor functions as transcriptional activator or repressor. ; FUNCTION: Isoform A: Ligand-dependent transdominant repressor of steroid hormone receptor transcriptional activity including repression of its isoform B, MR and ER. Transrepressional activity may involve recruitment of corepressor NCOR2. ; FUNCTION: Isoform B: Transcriptional activator of several progesteron-dependent promoters in a variety of cell types. Involved in activation of SRC-dependent MAPK signaling on hormone stimulation. ; FUNCTION: Isoform 4: Increases mitochondrial membrane potential and cellular respiration upon stimulation by progesterone.

> Gene Ontology
 
Biological Process GO:0006352 DNA-templated transcription, initiation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0009755 hormone-mediated signaling pathway
GO:0043401 steroid hormone mediated signaling pathway
GO:0048545 response to steroid hormone
GO:0071383 cellular response to steroid hormone stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003707 steroid hormone receptor activity
GO:0005496 steroid binding
GO:0051117 ATPase binding
Cellular Component GO:0005741 mitochondrial outer membrane
GO:0019867 outer membrane
GO:0031968 organelle outer membrane
> KEGG and Reactome Pathway
 
KEGG hsa04114 Oocyte meiosis
hsa04914 Progesterone-mediated oocyte maturation
Reactome R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-383280: Nuclear Receptor transcription pathway
R-HSA-1251985: Nuclear signaling by ERBB4
R-HSA-162582: Signal Transduction
R-HSA-1236394: Signaling by ERBB4
Summary
SymbolPGR
Nameprogesterone receptor
Aliases NR3C3; nuclear receptor subfamily 3 group C member 3
Chromosomal Location11q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PGR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PGR and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
21483002Breast Carcinoma (ERBB-(+))Inhibit immunity (infiltration)The total number of CD8(+) cells was positively correlated with tumor grade (r(s) = 0.20; P < .001) and inversely correlated with patient's age at diagnosis, estrogen receptor-alpha (ER-α), and progesterone receptor (PgR) expression (Mann-Whitney U test, P < .001).
Summary
SymbolPGR
Nameprogesterone receptor
Aliases NR3C3; nuclear receptor subfamily 3 group C member 3
Chromosomal Location11q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PGR in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPGR
Nameprogesterone receptor
Aliases NR3C3; nuclear receptor subfamily 3 group C member 3
Chromosomal Location11q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PGR in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2730.645
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4990.745
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0230.989
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0420.948
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7150.475
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.7180.496
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0660.897
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0530.94
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3940.0438
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PGR in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.75.5-1.81
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.76.8-3.11
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPGR
Nameprogesterone receptor
Aliases NR3C3; nuclear receptor subfamily 3 group C member 3
Chromosomal Location11q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PGR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPGR
Nameprogesterone receptor
Aliases NR3C3; nuclear receptor subfamily 3 group C member 3
Chromosomal Location11q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PGR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PGR.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPGR
Nameprogesterone receptor
Aliases NR3C3; nuclear receptor subfamily 3 group C member 3
Chromosomal Location11q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PGR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPGR
Nameprogesterone receptor
Aliases NR3C3; nuclear receptor subfamily 3 group C member 3
Chromosomal Location11q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PGR expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPGR
Nameprogesterone receptor
Aliases NR3C3; nuclear receptor subfamily 3 group C member 3
Chromosomal Location11q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PGR and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPGR
Nameprogesterone receptor
Aliases NR3C3; nuclear receptor subfamily 3 group C member 3
Chromosomal Location11q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PGR collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PGR.
ID Name Drug Type Targets #Targets
DB00294EtonogestrelSmall MoleculeESR1, PGR2
DB00304DesogestrelSmall MoleculeESR1, PGR2
DB00351Megestrol acetateSmall MoleculeNR3C1, PGR2
DB00367LevonorgestrelSmall MoleculeAR, ESR1, PGR, SHBG, SRD5A15
DB00378DydrogesteroneSmall MoleculePGR1
DB00396ProgesteroneSmall MoleculeAR, CYP17A1, ESR1, NR1I2, NR3C1, NR3C2, OPRK1, ORM1, PGR, SHBG10
DB00421SpironolactoneSmall MoleculeAR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, ......27
DB00431LindaneSmall MoleculeESR1, GABRB1, GABRB3, GABRR1, GLRA1, GLRA2, GLRA3, GLRB, NR1I2, PG ......10
DB00588Fluticasone propionateSmall MoleculeNR3C1, NR3C2, PGR, PLA2G4A4
DB00603Medroxyprogesterone acetateSmall MoleculeESR1, PGR2
DB00648MitotaneSmall MoleculeAR, CYP11B1, ESR1, FDX1, PGR5
DB00717NorethisteroneSmall MoleculePGR1
DB00764MometasoneSmall MoleculeNR3C1, PGR2
DB00823Ethynodiol diacetateSmall MoleculeESR1, PGR2
DB00834MifepristoneSmall MoleculeKLK3, NR1I2, NR3C1, PGR4
DB00957NorgestimateSmall MoleculeAR, ESR1, PGR3
DB01395DrospirenoneSmall MoleculeAR, NR3C2, PGR3
DB01406DanazolSmall MoleculeAR, CCL2, ESR1, GNRHR, PGR5
DB01428OxybenzoneSmall MoleculeAR, ESR1, ESR2, PGR4
DB01431AllylestrenolSmall MoleculeESR1, PGR2
DB02746Phthalic AcidSmall MoleculeESR1, ESR2, PGR, PPARA, PPARD, PPARG, RXRA, RXRB, RXRG9
DB02998MethyltrienoloneSmall MoleculeAR, NCOA2, NR3C2, PGR4
DB04787TanaprogetSmall MoleculePGR1
DB05253ProellexSmall MoleculePGR1
DB06680AsoprisnilSmall MoleculePGR1
DB06713NorelgestrominSmall MoleculeALB, AR, PGR3
DB06789Hydroxyprogesterone caproateSmall MoleculePGR1
DB08867UlipristalSmall MoleculeAR, NR3C1, PGR3
DB09123DienogestSmall MoleculeAR, PGR2
DB09124MedrogestoneSmall MoleculePGR1
DB09389NorgestrelSmall MoleculeAR, PGR, SRD5A13
DB11064HomosalateSmall MoleculeAR, ESR1, PGR3
DB11219EnzacameneSmall MoleculeAR, ESR1, ESR2, PGR4
DB11619GestrinoneSmall MoleculeAR, ESR1, GNRHR, NR3C1, PGR, SHBG6